The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor

Zhiqing, Liang

Status: Unknown

Conditions: Gynecologic Malignant Tumor

Study type: Observational

Funder types: Other

Identifiers

NCT02166515

001

fck001 (Registry Identifier)

Details and patient eligibility

About

As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies. In recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising.

The key to gynecologic malignancies is how to early diagnose and treat. With the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. Genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. Therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.

Enrollment: 200 estimated patients

Sex: Female

Ages: 16 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Female aging from 16 to 75-year old;
• Preoperative diagnosis of gynecologic malignancies;
• Have the ability to comply with Research programs;
• Voluntarily participate in the study and signed an informed consent form

Exclusion criteria

• The cases do not meet the inclusion criteria should be removed from,indicating the reason for excluding.

Trial design

200 participants in 2 patient groups

experiment group

Description:

patients with cervical cancer, endometrial cancers or ovary cancer

control group

Description:

postmenopausal women with benign tumor